非小细胞肺癌EGFR-T790M突变药物的研究进展

Research progress on non-small cell lung cancer EGFR-T790M mutation drugs

原发性肺癌(简称肺癌)是常见的恶性肿瘤之一,发生率居恶性肿瘤首位。非小细胞肺癌(NSCLC)约占所有肺癌的80%。近年来,表皮生长因子受体–酪氨酸激酶抑制(EGFR-TKI)在NSCLC治疗中起到重要作用;随着EGFR-TKI在临床上的广泛应用,耐药问题日益加剧;T790M基因突变是导致EGFR-TKI获得性耐药最主要的机制。全球新批准并上市的治疗NSCLC EGFR-T790M突变的药物有brigatinib、奥莫替尼、atezolizumab等;处于上市申请阶段的有丁磺氨酸、阿拉莫林盐酸盐、ABP-215;处于研发阶段的主要有naquotinib、TG-4010等。对近年来处于研发后期的NSCLC治疗药物进行详细介绍,同时对抗NSCLC药物的未来发展方向进行了展望,以期为抗NSCLC药物的研发提供参考。

Primary lung cancer（referred to as lung cancer） is one of the common malignant tumors, and the incidence ranks the first of malignant tumors. Non-small cell lung cancer（NSCLC） accounts for about 80% of all lung cancer. In recent years, epidermal growth factor receptor-tyrosine kinase inhibition（EGFR-TKI） plays an important role in the treatment of NSCLC. With the extensive application of EGFR-TKI in clinical practice, the resistance problem is increasing. T790M gene mutation is leading to EGFR-TKI acquired resistance to the most important mechanism. Newly approved and marketed drugs for the treatment of NSCLC EGFR-T790M mutations include brigatinib, olmutinib, atezolizumab, etc.; Butylene acid, anamorelin hydrochloride and ABP-215 are in abbreviated new drug application, and naquotinib and TG-4010 are under development. The development of NSCLC in late development in recent years has been described in detail, and the future development direction of NSCLC drugs is also discussed in order to provide reference for the development of anti-NSCLC drugs.